Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Public ClinicalTrials.gov record NCT00547066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
Study identification
- NCT ID
- NCT00547066
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2007 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Nov 2011 (Actual)
- Last update posted
- Aug 16, 2021
2007 – 2011
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California- Keck School of Medicine | Los Angeles | California | 90033 | — |
| Center of Hope for Cancer and Blood Disorders | Riverdale | Georgia | 30274 | — |
| Georgia Cancer Specialtists | Tucker | Georgia | 30084 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Hematology Oncology Specialists | Metairie | Louisiana | 70006 | — |
| Not listed | Denville | New Jersey | 07834 | — |
| Hematology/Oncology Specialists | Buffalo | New York | 14215 | — |
| New York Presbyterian Hospital Weill Cornell Medical Center | New York | New York | 10021 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00547066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2021 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00547066 live on ClinicalTrials.gov.